225 related articles for article (PubMed ID: 35812443)
1. Computational Recognition of a Regulatory T-cell-specific Signature With Potential Implications in Prognosis, Immunotherapy, and Therapeutic Resistance of Prostate Cancer.
Ju M; Fan J; Zou Y; Yu M; Jiang L; Wei Q; Bi J; Hu B; Guan Q; Song X; Dong M; Wang L; Yu L; Wang Y; Kang H; Xin W; Zhao L
Front Immunol; 2022; 13():807840. PubMed ID: 35812443
[TBL] [Abstract][Full Text] [Related]
2. Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer.
Maeda S; Motegi T; Iio A; Kaji K; Goto-Koshino Y; Eto S; Ikeda N; Nakagawa T; Nishimura R; Yonezawa T; Momoi Y
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131860
[TBL] [Abstract][Full Text] [Related]
3. Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors.
Andersen LB; Nørgaard M; Rasmussen M; Fredsøe J; Borre M; Ulhøi BP; Sørensen KD
J Pathol; 2021 Oct; 255(2):155-165. PubMed ID: 34255349
[TBL] [Abstract][Full Text] [Related]
4. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
[TBL] [Abstract][Full Text] [Related]
5. FoxP3
Saleh R; Elkord E
Cancer Lett; 2020 Oct; 490():174-185. PubMed ID: 32721551
[TBL] [Abstract][Full Text] [Related]
6. Investigation on the regulatory T cells signature and relevant Foxp3/STAT3 axis in esophageal cancer.
Yang L; Zhao Q; Wang X; Pilapong C; Li Y; Zou J; Jin J; Rong J
Cancer Med; 2023 Feb; 12(4):4993-5008. PubMed ID: 36226375
[TBL] [Abstract][Full Text] [Related]
7. The role of regulatory T cells in the pathogenesis and treatment of prostate cancer.
Karpisheh V; Mousavi SM; Naghavi Sheykholeslami P; Fathi M; Mohammadpour Saray M; Aghebati-Maleki L; Jafari R; Majidi Zolbanin N; Jadidi-Niaragh F
Life Sci; 2021 Nov; 284():119132. PubMed ID: 33513396
[TBL] [Abstract][Full Text] [Related]
8. Increased infiltration of CCR4-positive regulatory T cells in prostate cancer tissue is associated with a poor prognosis.
Watanabe M; Kanao K; Suzuki S; Muramatsu H; Morinaga S; Kajikawa K; Kobayashi I; Nishikawa G; Kato Y; Zennami K; Nakamura K; Tsuzuki T; Yoshikawa K; Ueda R; Sumitomo M
Prostate; 2019 Oct; 79(14):1658-1665. PubMed ID: 31390096
[TBL] [Abstract][Full Text] [Related]
9. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.
Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S
Front Immunol; 2023; 14():1263537. PubMed ID: 37767092
[TBL] [Abstract][Full Text] [Related]
10. Regulatory T-cells-related signature for identifying a prognostic subtype of hepatocellular carcinoma with an exhausted tumor microenvironment.
Zhang G
Front Immunol; 2022; 13():975762. PubMed ID: 36189226
[TBL] [Abstract][Full Text] [Related]
11. Revealing the role of regulatory T cells in the tumor microenvironment of lung adenocarcinoma: a novel prognostic and immunotherapeutic signature.
Zhang P; Zhang X; Cui Y; Gong Z; Wang W; Lin S
Front Immunol; 2023; 14():1244144. PubMed ID: 37671160
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel stemness-related signature with appealing implications in discriminating the prognosis and therapy responses for prostate cancer.
Zhang T; Li J; Dai J; Yuan F; Yuan G; Chen H; Zhu D; Mao X; Qin L; Liu N; Yang M
Cancer Genet; 2023 Aug; 276-277():48-59. PubMed ID: 37487324
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
Nishikawa H; Koyama S
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330764
[TBL] [Abstract][Full Text] [Related]
14. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
[TBL] [Abstract][Full Text] [Related]
15. Expression of costimulatory and inhibitory receptors in FoxP3
Toker A; Ohashi PS
Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
[TBL] [Abstract][Full Text] [Related]
16. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer.
Stultz J; Fong L
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):697-717. PubMed ID: 33820953
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of a tumor-infiltrating Treg transcriptional signature conserved across species and tumor types.
Magnuson AM; Kiner E; Ergun A; Park JS; Asinovski N; Ortiz-Lopez A; Kilcoyne A; Paoluzzi-Tomada E; Weissleder R; Mathis D; Benoist C
Proc Natl Acad Sci U S A; 2018 Nov; 115(45):E10672-E10681. PubMed ID: 30348759
[TBL] [Abstract][Full Text] [Related]
18. Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy.
Peng S; Hu P; Xiao YT; Lu W; Guo D; Hu S; Xie J; Wang M; Yu W; Yang J; Chen H; Zhang X; Zhu Y; Wang Y; Yang Y; Zhu G; Chen S; Wang J; Zhang B; Chen W; Wu H; Sun Z; Ding T; Zhang H; Yi Z; Liu M; Ren S
Clin Cancer Res; 2022 Feb; 28(3):552-567. PubMed ID: 34740924
[TBL] [Abstract][Full Text] [Related]
19. Roles of regulatory T cells in cancer immunity.
Takeuchi Y; Nishikawa H
Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]